Celgene Corporation Logo

E-mail this page: News Release

Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting

For security reasons, registration is required before you can use this feature.
* Indicates required field